Company overview
ChronoProof is building an intelligence layer for venture investors evaluating and managing healthcare and medical-device opportunities. The goal is to help firms underwrite healthcare like a specialist by improving diligence quality, surfacing regulatory and market risk earlier, strengthening portfolio monitoring, and adding more rigor to exit timing decisions.
The current product suite includes five connected products:
with AI-Powered GRC Intelligence and Due Diligence
ChronoScout
Front-end discovery and diligence support for identifying, screening, and framing opportunities.
ChronoTruth
Claims validation and compliance intelligence, especially where factual accuracy, evidence, and risk need to be checked.
ChronoSee
Synthesis and insight layer that helps turn fragmented information into an investor-readable view.
ChronoPulse
Monitoring and ongoing signal tracking for portfolio companies or active diligence targets.
ChronoCurve
AI-enhanced strategy for exit timing, value inflection tracking, and portfolio-level decision support.
The working thesis is that these should not be viewed as unrelated tools, but as one decision stack across the investment lifecycle: source, validate, understand, monitor, and optimize exit timing.
The current product framing is:
ChronoScout
“Find and frame the opportunity.”
ChronoTruth
“Verify the claims and risks.”
ChronoSee
“See the full picture clearly.”
ChronoPulse
“Monitor what is changing over time.”
ChronoCurve
“Know when value is peaking and when to act.”
Customer and problem
The initial target customer is a venture capital firm that wants exposure to healthcare, medtech, diagnostics, digital health, or adjacent regulated categories, but does not always have deep internal sector-specialist bandwidth. The strongest fit may be either generalist VCs doing healthcare deals or healthcare-focused funds looking to improve speed, consistency, and decision quality.
The core problem is not a lack of raw information. It is that healthcare investing requires stitching together clinical, regulatory, reimbursement, market, diligence, and portfolio signals into a decision process that is usually manual, fragmented, and partner-dependent. That creates slower diligence, inconsistent judgment, avoidable blind spots, and weak institutional memory.